[go: up one dir, main page]

TR201910825T4 - Yemek borusu rahatsizliklarini tedavi̇ etmek i̇çi̇n yöntemler ve bi̇leşi̇mler - Google Patents

Yemek borusu rahatsizliklarini tedavi̇ etmek i̇çi̇n yöntemler ve bi̇leşi̇mler Download PDF

Info

Publication number
TR201910825T4
TR201910825T4 TR2019/10825T TR201910825T TR201910825T4 TR 201910825 T4 TR201910825 T4 TR 201910825T4 TR 2019/10825 T TR2019/10825 T TR 2019/10825T TR 201910825 T TR201910825 T TR 201910825T TR 201910825 T4 TR201910825 T4 TR 201910825T4
Authority
TR
Turkey
Prior art keywords
treat
compositions
methods
diseases
meal pipe
Prior art date
Application number
TR2019/10825T
Other languages
English (en)
Inventor
G Currie Mark
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of TR201910825T4 publication Critical patent/TR201910825T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut başvuru genel olarak kolesevelam, kolesevelam hidroklorür, kolestipol, sevelamer veya bunların bir kombinasyonunun yemek borusu rahatsızlıklarının tedavisinde kullanılması ile ilgilidir.
TR2019/10825T 2006-12-22 2007-12-21 Yemek borusu rahatsizliklarini tedavi̇ etmek i̇çi̇n yöntemler ve bi̇leşi̇mler TR201910825T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87149906P 2006-12-22 2006-12-22

Publications (1)

Publication Number Publication Date
TR201910825T4 true TR201910825T4 (tr) 2019-08-21

Family

ID=39277294

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10825T TR201910825T4 (tr) 2006-12-22 2007-12-21 Yemek borusu rahatsizliklarini tedavi̇ etmek i̇çi̇n yöntemler ve bi̇leşi̇mler

Country Status (19)

Country Link
US (4) US9205094B2 (tr)
EP (4) EP2478895A3 (tr)
JP (2) JP2010514702A (tr)
AU (1) AU2007336731B2 (tr)
CA (1) CA2673665C (tr)
CY (1) CY1122009T1 (tr)
DK (1) DK2124884T3 (tr)
ES (1) ES2739542T3 (tr)
HU (1) HUE046465T2 (tr)
IL (1) IL199477A (tr)
LT (1) LT2124884T (tr)
NZ (2) NZ578204A (tr)
PL (1) PL2124884T3 (tr)
PT (1) PT2124884T (tr)
RU (3) RU2491075C2 (tr)
SI (1) SI2124884T1 (tr)
TR (1) TR201910825T4 (tr)
WO (1) WO2008080092A2 (tr)
ZA (1) ZA200904573B (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478895A3 (en) 2006-12-22 2012-12-19 Ironwood Pharmaceuticals, Inc. Compositions for treating esophageal disorders
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI605837B (zh) * 2011-01-27 2017-11-21 Kowa Co Ltd Pharmaceutical composition containing water-insoluble drug and pharmaceutical preparation
ITRM20120041A1 (it) * 2012-02-08 2013-08-09 Dicofarm Spa "prodotto a base di glucomannano e chitosano utile per il trattamento del reflusso gastroesofageo"
CN105338958A (zh) * 2013-01-15 2016-02-17 铁木医药有限公司 胆汁酸螯合剂的胃内滞留缓释口服剂型
US20170095432A1 (en) 2014-06-13 2017-04-06 United Therapeutics Corporation Treprostinil formulations
TWI705814B (zh) * 2014-06-20 2020-10-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
US11229643B2 (en) * 2016-11-02 2022-01-25 Novartis Ag Combinations of FGFR4 inhibitors and bile acid sequestrants
RU2667651C1 (ru) * 2017-12-26 2018-09-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения эрозивной формы гастроэзофагеальной рефлюксной болезни у пациентов, получающих химиотерапию
EP3863643A4 (en) * 2018-10-12 2022-07-27 Icahn School of Medicine at Mount Sinai Azd3355 (lesogaberan) for treatment and prevention of nonalcoholic steatohepatitis (nash), liver fibrosis, and other liver conditions
WO2021212022A1 (en) * 2020-04-16 2021-10-21 The Medical College Of Wisconsin, Inc. Aerosolized formulations of hiv protease inhibitors for the treatment of airway reflux

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624209A (en) * 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
US3692895A (en) 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
DE2704425C2 (de) * 1977-02-03 1982-10-07 Interx Research Corp., 66044 Lawrence, Kan. Verwendung von Styrol-Divinylbenzol-Copolymer-Anionenaustauscherharzen bei der Bekämpfung von Magengeschwüren
GB1566609A (en) * 1977-03-10 1980-05-08 Reckitt & Colmann Prod Ltd Pharmaceutical compositions containing cholestyramine and alginic acid
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS5692217A (en) 1979-12-26 1981-07-25 Kowa Co Easily absorbable enzyme preparation
US4359465A (en) 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
US4472409A (en) 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
AU545463B2 (en) 1982-06-25 1985-07-18 Kowa Co. Ltd. Benzoyl piperacine esters
SE8300736D0 (sv) 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS59222484A (ja) 1983-06-02 1984-12-14 Kowa Co テトラヒドロナフチルカルボン酸フエニルエステル誘導体
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US4735804A (en) 1985-05-10 1988-04-05 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4738975A (en) 1985-07-02 1988-04-19 Takeda Chemical Industries, Ltd. Pyridine derivatives, and use as anti-ulcer agents
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US4851232A (en) 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
FI96860C (fi) 1987-06-17 1996-09-10 Eisai Co Ltd Analogiamenetelmä lääkeaineena käytettävän pyridiinijohdannaisen valmistamiseksi
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
JP2916206B2 (ja) 1990-04-28 1999-07-05 帝國製薬株式会社 生理活性ペプチド
JP2916205B2 (ja) 1990-04-28 1999-07-05 帝國製薬株式会社 生理活性ペプチド
DK223790D0 (da) 1990-09-18 1990-09-18 Novo Nordisk As Proteaseholdig detergentkomposition
US5312824A (en) 1990-10-17 1994-05-17 Takeda Chemical Industries, Ltd. Certain 2-[(4-difluoromethoxy-2-pyridyl)-methylthio or methylsulfinyl-5-benzimidazoles useful for treating peptic ulcers
US5167483A (en) 1990-12-24 1992-12-01 Gardiner Samuel W Method for utilizing angular momentum in energy conversion devices and an apparatus therefore
IT1245891B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5670163A (en) 1994-06-20 1997-09-23 Kv Pharmaceuticals Company Long acting GI and esophageal protectant
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
DE19534996A1 (de) 1995-09-21 1997-03-27 Bosch Gmbh Robert Verfahren zur Verbrennungsaussetzererkennung durch Auswertung von Drehzahlschwankungen
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
ES2234139T3 (es) 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
US20040062802A1 (en) * 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
DE19850309A1 (de) 1998-10-30 2000-05-04 Lohmann Therapie Syst Lts Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer
IL133196A0 (en) 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US6638498B2 (en) * 2000-06-30 2003-10-28 Semorex Inc. Molecularly imprinted polymers for the treatment and diagnosis of medical conditions
ES2240516T3 (es) 2000-07-28 2005-10-16 F. Hoffmann-La Roche Ag Nuevo uso de los inhibidores de lipasa.
AU2001289699B2 (en) * 2000-07-28 2006-06-01 Cheplapharm Arzneimittel Gmbh New pharmaceutical composition
US20030031711A1 (en) * 2001-05-29 2003-02-13 Fara John W. Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
KR20040018394A (ko) * 2001-07-04 2004-03-03 썬 파마슈티컬 인더스트리스 리미티드 위 정체 제어되는 약물 전달 계
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
AU2003206382B2 (en) 2002-01-03 2008-01-24 Smithkline Beecham Corporation Novel pharmaceutical dosage forms and method for producing same
US20030219401A1 (en) * 2002-03-18 2003-11-27 Keller Bradley T. Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
GB0209481D0 (en) 2002-04-24 2002-06-05 Novartis Ag Organic compounds
WO2004002445A2 (en) 2002-06-26 2004-01-08 Cadila Healthcare Limited Novel floating dosage form
US20040043072A1 (en) * 2002-09-04 2004-03-04 Will Joanne Patricia Alleviation of upper gastrointestinal irritation
JP2006506362A (ja) 2002-10-11 2006-02-23 デポメド・ディベロップメント・リミテッド 胃内保持型レボドパデリバリー形態
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
EP1680099B1 (en) * 2003-11-07 2009-04-15 JJ Pharma, Inc. Hdl-boosting combination therapy complexes
US20070196396A1 (en) 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20070212325A1 (en) * 2004-03-26 2007-09-13 Mitsubishi Pharma Corporation Insulin Resistance-Improving Agent
FR2874325B1 (fr) 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20060073213A1 (en) * 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
WO2006035418A2 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
EP1843755B1 (en) * 2005-02-01 2015-04-01 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
WO2006088305A1 (en) * 2005-02-15 2006-08-24 Chong Kun Dang Pharmaceutical Corp. Gastric-retentive controlled release mono-matrix tablet
EP1877067A1 (en) * 2005-04-26 2008-01-16 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
WO2007137216A2 (en) 2006-05-22 2007-11-29 Janssen Pharmaceutica, N.V. Gastroretentive sustained release formulations
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
EP2478895A3 (en) 2006-12-22 2012-12-19 Ironwood Pharmaceuticals, Inc. Compositions for treating esophageal disorders
WO2009158625A2 (en) 2008-06-26 2009-12-30 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders

Also Published As

Publication number Publication date
ES2739542T3 (es) 2020-01-31
HUE046465T2 (hu) 2020-03-30
LT2124884T (lt) 2019-08-26
EP2124884A2 (en) 2009-12-02
EP3628307A1 (en) 2020-04-01
WO2008080092A3 (en) 2008-11-20
NZ598728A (en) 2013-09-27
PT2124884T (pt) 2019-09-17
EP2478894A2 (en) 2012-07-25
WO2008080092A2 (en) 2008-07-03
NZ578204A (en) 2012-05-25
JP6141891B2 (ja) 2017-06-07
US20170290767A1 (en) 2017-10-12
US20180235878A1 (en) 2018-08-23
CA2673665A1 (en) 2008-07-03
US20100179235A1 (en) 2010-07-15
AU2007336731A1 (en) 2008-07-03
PL2124884T3 (pl) 2020-01-31
JP2010514702A (ja) 2010-05-06
SI2124884T1 (sl) 2019-09-30
RU2013117758A (ru) 2014-10-27
US9205094B2 (en) 2015-12-08
EP2124884B1 (en) 2019-07-10
RU2009128202A (ru) 2011-01-27
CA2673665C (en) 2017-03-21
IL199477A (en) 2017-07-31
ZA200904573B (en) 2010-09-29
AU2007336731A2 (en) 2009-08-06
CY1122009T1 (el) 2020-10-14
WO2008080092A8 (en) 2009-03-05
EP2478895A3 (en) 2012-12-19
JP2015212250A (ja) 2015-11-26
EP2478894A3 (en) 2012-12-19
AU2007336731B2 (en) 2013-08-29
RU2705364C2 (ru) 2019-11-07
US20160051577A1 (en) 2016-02-25
EP2478895A2 (en) 2012-07-25
RU2491075C2 (ru) 2013-08-27
RU2019134181A (ru) 2021-04-26
DK2124884T3 (da) 2019-08-05

Similar Documents

Publication Publication Date Title
TR201910825T4 (tr) Yemek borusu rahatsizliklarini tedavi̇ etmek i̇çi̇n yöntemler ve bi̇leşi̇mler
TW200738263A (en) ANG2 and VEGF inhibitor combinations
WO2007095186A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
ATE553198T1 (de) Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten
PH12012501067A1 (en) Combination therapy for treating cancer and diagnostic assays for use therein
CL2008002381A1 (es) Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer.
MX2010007936A (es) Anticuerpo anti-nr-10 y su uso.
EP1987141A4 (en) COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-CONDITIONAL DISEASES
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
UA94221C2 (en) Lipocalin protein
NZ593474A (en) Compositions and methods for treatment of celiac disease
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
NI201000093A (es) Toalla para llevar puesta
MX2009013725A (es) Composiciones de fragmentos de tejido para el tratamiento de la incontinencia.
EA201070609A1 (ru) Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
SG157365A1 (en) Compositions and methods for treating neoplastic diseases
JO3358B1 (ar) معالجات حساسية العيون
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
WO2008010991A3 (en) Methods and compositions for the treatment of cancer